Identification

Name
Desipramine
Accession Number
DB01151  (APRD00022, DB07682)
Type
Small Molecule
Groups
Approved
Description

Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).

Structure
Thumb
Synonyms
  • 3-(10,11-DIHYDRO-5H-dibenzo[b,F]azepin-5-yl)-N-methylpropan-1-amine
  • 5-(gamma-Methylaminopropyl)iminodibenzyl
  • 5-(γ-methylaminopropyl)iminodibenzyl
  • Déméthylimipramine
  • Desipramin
  • Desipramina
  • Desipramine
  • Desipraminum
  • Desmethylimipramine
  • DMI
  • Monodemethylimipramine
  • N-(3-methylaminopropyl)iminobibenzyl
  • Norimipramine
Product Ingredients
IngredientUNIICASInChI Key
Desipramine Hydrochloride1Y58DO4MY158-28-6XAEWZDYWZHIUCT-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DesipramineTablet100 mgOralAa Pharma Inc1996-12-31Not applicableCanada
DesipramineTablet10 mgOralAa Pharma Inc1996-12-31Not applicableCanada
DesipramineTablet75 mgOralAa Pharma Inc1996-12-31Not applicableCanada
DesipramineTablet25 mgOralAa Pharma Inc1996-12-31Not applicableCanada
DesipramineTablet50 mgOralAa Pharma Inc1996-12-31Not applicableCanada
Desipramine HydrochlorideTablet, sugar coated50 mg/1OralWinthrop U.S.2014-04-01Not applicableUs
Desipramine HydrochlorideTablet, sugar coated150 mg/1OralWinthrop U.S.2014-04-01Not applicableUs
Desipramine HydrochlorideTablet, sugar coated10 mg/1OralWinthrop U.S.2014-04-01Not applicableUs
Desipramine HydrochlorideTablet, sugar coated75 mg/1OralWinthrop U.S.2014-04-01Not applicableUs
Desipramine HydrochlorideTablet, sugar coated25 mg/1OralWinthrop U.S.2014-04-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desipramine HydrochlorideTablet10 mg/1OralHeritage2016-11-01Not applicableUs
Desipramine HydrochlorideTablet, film coated10 mg/1OralKaiser Foundations Hospitals2012-05-31Not applicableUs
Desipramine HydrochlorideTablet100 mg/1OralHeritage2016-11-01Not applicableUs
Desipramine HydrochlorideTablet, film coated10 mg/1OralSandoz1988-05-242016-12-31Us
Desipramine HydrochlorideTablet, film coated100 mg/1OralSandoz1988-06-20Not applicableUs
Desipramine HydrochlorideTablet, film coated10 mg/1OralCore Pharma, Llc2017-01-20Not applicableUs
Desipramine HydrochlorideTablet10 mg/1OralRemedy Repack2011-04-182016-10-13Us
Desipramine HydrochlorideTablet, film coated100 mg/1Oralbryant ranch prepack1988-06-20Not applicableUs
Desipramine HydrochlorideTablet, film coated100 mg/1OralCore Pharma, Llc2017-01-20Not applicableUs
Desipramine HydrochlorideTablet, film coated75 mg/1OralCore Pharma, Llc2017-01-20Not applicableUs
International/Other Brands
Pertofran (Ciba) / Pertofrane (USV)
Categories
UNII
TG537D343B
CAS number
50-47-5
Weight
Average: 266.3807
Monoisotopic: 266.178298714
Chemical Formula
C18H22N2
InChI Key
HCYAFALTSJYZDH-UHFFFAOYSA-N
InChI
InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3
IUPAC Name
(3-{2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine
SMILES
CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12

Pharmacology

Indication

For relief of symptoms in various depressive syndromes, especially endogenous depression. It has also been used to manage chronic peripheral neuropathic pain, as a second line agent for the management of anxiety disorders (e.g. panic disorder, generalized anxiety disorder), and as a second or third line agent in the ADHD management.

Structured Indications
Pharmacodynamics

Desipramine, a secondary amine tricyclic antidepressant, is structurally related to both the skeletal muscle relaxant cyclobenzaprine and the thioxanthene antipsychotics such as thiothixene. It is the active metabolite of imipramine, a tertiary amine TCA. The acute effects of desipramine include inhibition of noradrenaline re-uptake at noradrenergic nerve endings and inhibition of serotonin (5-hydroxy tryptamine, 5HT) re-uptake at the serotoninergic nerve endings in the central nervous system. Desipramine exhibits greater noradrenergic re-uptake inhibition compared to the tertiary amine TCA imipramine. In addition to inhibiting neurotransmitter re-uptake, desipramine down-regulates beta-adrenergic receptors in the cerebral cortex and sensitizes serotonergic receptors with chronic use. The overall effect is increased serotonergic transmission. Antidepressant effects are typically observed 2 - 4 weeks following the onset of therapy though some patients may require up to 8 weeks of therapy prior to symptom improvement. Patients experiencing more severe depressive episodes may respond quicker than those with mild depressive symptoms.

Mechanism of action

Desipramine is a tricyclic antidepressant (TCA) that selectively blocks reuptake of norepinephrine (noradrenaline) from the neuronal synapse. It also inhibits serotonin reuptake, but to a lesser extent compared to tertiary amine TCAs such as imipramine. Inhibition of neurotransmitter reuptake increases stimulation of the post-synaptic neuron. Chronic use of desipramine also leads to down-regulation of beta-adrenergic receptors in the cerebral cortex and sensitization of serotonergic receptors. An overall increase in serotonergic transmission likely confers desipramine its antidepressant effects. Desipramine also possesses minor anticholinergic activity, through its affinity for muscarinic receptors. TCAs are believed to act by restoring normal levels of neurotransmitters via synaptic reuptake inhibition and by increasing serotonergic neurotransmission via serotonergic receptor sensitization in the central nervous system.

TargetActionsOrganism
ASodium-dependent noradrenaline transporter
inhibitor
Human
ASodium-dependent serotonin transporter
inhibitor
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
UBeta-1 adrenergic receptor
other
Human
USphingomyelin phosphodiesterase
inhibitor
Human
NHistamine H1 receptor
antagonist
Human
NAlpha-1 adrenergic receptors
antagonist
Human
NMuscarinic acetylcholine receptor M1
antagonist
Human
NMuscarinic acetylcholine receptor M2
antagonist
Human
NMuscarinic acetylcholine receptor M3
antagonist
Human
NMuscarinic acetylcholine receptor M4
antagonist
Human
NMuscarinic acetylcholine receptor M5
antagonist
Human
U5-hydroxytryptamine receptor 1A
binder
Human
U5-hydroxytryptamine receptor 2C
binder
Human
UD(2) dopamine receptor
binder
Human
UAlpha-2 adrenergic receptors
binder
Human
Absorption

Desipramine hydrochloride is rapidly and almost completely absorbed from the gastrointestinal tract. It undergoes extensive first-pass metabolism. Peak plasma concentrations are attained 4 - 6 hours following oral administration.

Volume of distribution
Not Available
Protein binding

73-92% bound to plasma proteins

Metabolism

Desipramine is extensively metabolized in the liver by CYP2D6 (major) and CYP1A2 (minor) to 2-hydroxydesipramine, an active metabolite. 2-hydroxydesipramine is thought to retain some amine reuptake inhibition and may possess cardiac depressant activity. The 2-hydroxylation metabolic pathway of desipramine is under genetic control.

Route of elimination

Desipramine is metabolized in the liver, and approximately 70% is excreted in the urine.

Half life

7-60+ hours; 70% eliminated renally

Clearance
Not Available
Toxicity

Male mice: LD50 = 290 mg/kg, female rats: LD50 = 320 mg/kg. Antagonism of the histamine H1 and α1 receptors can lead to sedation and hypotension. Antimuscarinic activity confers anticholinergic side effects such as blurred vision, dry mouth, constipation and urine retention may occur. Cardiotoxicity may occur with high doses of desipramine. Cardiovascular side effects in postural hypotension, tachycardia, hypertension, ECG changes and congestive heart failure. Psychotoxic effects include impaired memory and delirium. Induction of hypomanic or manic episodes may occur in patients with a history of bipolar disorder. Withdrawal symptoms include GI disturbances (e.g. nausea, vomiting, abdominal pain, diarrhea), anxiety, insomnia, nervousness, headache and malaise.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Desipramine Action PathwayDrug action
Imipramine Action PathwayDrug action
Imipramine Metabolism PathwayDrug metabolism
Desipramine Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*4(A;A)A AlleleEffect Directly StudiedPatients with this genotype have reduced metabolism of desipramine.Details
Cytochrome P450 2D6CYP2D6*3Not Available2549delAEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableA alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableG alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.Details
Cytochrome P450 2D6CYP2D6*4Not Available3877G>AEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.Details

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Desipramine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineDesipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Desipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineDesipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Desipramine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineDesipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineDesipramine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Desipramine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Desipramine.Experimental
AbirateroneThe serum concentration of Desipramine can be increased when it is combined with Abiraterone.Approved
AcenocoumarolDesipramine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Desipramine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Desipramine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Desipramine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Desipramine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Desipramine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Desipramine.Approved
AgmatineDesipramine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Desipramine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Desipramine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Desipramine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Desipramine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Desipramine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Desipramine.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Desipramine.Approved, Investigational
AlogliptinThe serum concentration of Desipramine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Desipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Desipramine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Desipramine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desipramine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Desipramine.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Desipramine.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Desipramine.Approved, Withdrawn
AmiodaroneDesipramine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Desipramine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desipramine.Approved
AmobarbitalThe metabolism of Desipramine can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desipramine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Desipramine.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Desipramine.Approved, Illicit
AmprenavirThe serum concentration of Desipramine can be increased when it is combined with Amprenavir.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Desipramine.Approved
AnagrelideDesipramine may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Desipramine.Approved
Antithrombin III humanThe serum concentration of Desipramine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Desipramine can be increased when it is combined with Apixaban.Approved
ApomorphineDesipramine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineDesipramine may decrease the antihypertensive activities of Apraclonidine.Approved
AprindineThe metabolism of Aprindine can be decreased when combined with Desipramine.Approved
AprotininThe serum concentration of Desipramine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Desipramine is combined with Arbutamine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Desipramine.Approved, Investigational
ArgatrobanThe serum concentration of Desipramine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Desipramine.Approved, Investigational
ArmodafinilThe metabolism of Desipramine can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideDesipramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherDesipramine may increase the QTc-prolonging activities of Artemether.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Desipramine resulting in a loss in efficacy.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Desipramine.Approved
AsenapineDesipramine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Desipramine.Approved, Withdrawn
AsunaprevirThe serum concentration of Desipramine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Desipramine can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Desipramine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Desipramine is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Desipramine.Investigational, Vet Approved
AzelastineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinDesipramine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Desipramine.Approved
BambuterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Bambuterol.Approved, Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Desipramine.Investigational
BarbexacloneThe metabolism of Desipramine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Desipramine can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Desipramine can be increased when it is combined with Batimastat.Experimental
BedaquilineDesipramine may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe serum concentration of Desipramine can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Desipramine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Desipramine.Investigational
BenzamidineThe serum concentration of Desipramine can be increased when it is combined with Benzamidine.Experimental
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Desipramine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Desipramine.Approved
BenzphetamineDesipramine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Desipramine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Desipramine.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Desipramine.Approved
BethanidineDesipramine may decrease the antihypertensive activities of Bethanidine.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Desipramine is combined with Bifeprunox.Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Desipramine.Approved
BivalirudinThe serum concentration of Desipramine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Desipramine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Desipramine can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Desipramine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Desipramine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Desipramine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Desipramine.Approved, Investigational
BrofaromineBrofaromine may increase the serotonergic activities of Desipramine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desipramine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Desipramine.Experimental
BromocriptineDesipramine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Desipramine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Desipramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Desipramine.Approved, Investigational, Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Desipramine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Desipramine.Approved, Investigational
BuprenorphineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Desipramine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Desipramine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desipramine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Desipramine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Desipramine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Desipramine.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Desipramine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desipramine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Desipramine.Approved
CaffeineThe metabolism of Desipramine can be decreased when combined with Caffeine.Approved
CamostatThe serum concentration of Desipramine can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Desipramine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Desipramine can be increased when it is combined with Candoxatrilat.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Desipramine.Investigational
CaptoprilThe serum concentration of Desipramine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Desipramine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Desipramine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Desipramine.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Desipramine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desipramine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Desipramine.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Desipramine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Desipramine.Approved, Investigational
CelecoxibThe metabolism of Desipramine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Desipramine is combined with Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Desipramine.Approved, Vet Approved
CeritinibDesipramine may increase the QTc-prolonging activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Desipramine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Desipramine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Desipramine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Desipramine.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Desipramine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Desipramine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Desipramine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desipramine.Approved
ChloroquineDesipramine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Desipramine.Approved
ChlorphentermineDesipramine may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Chlorproethazine.Experimental
ChlorpromazineDesipramine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Desipramine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Desipramine.Approved
CholecalciferolThe metabolism of Desipramine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Desipramine can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Desipramine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Desipramine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Desipramine can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Desipramine.Approved
CimetidineThe metabolism of Desipramine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Desipramine can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desipramine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Desipramine.Approved, Investigational
CiprofloxacinDesipramine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineDesipramine may increase the vasopressor activities of Cirazoline.Experimental
CisaprideDesipramine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Desipramine is combined with Citalopram.Approved
ClarithromycinDesipramine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Desipramine can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Desipramine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Desipramine.Approved
ClobazamThe metabolism of Desipramine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Desipramine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Desipramine.Approved, Illicit
ClonidineDesipramine may decrease the antihypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Desipramine.Experimental
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Desipramine.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desipramine.Approved, Illicit
ClorindioneDesipramine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Desipramine.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Desipramine.Approved, Illicit
ClotrimazoleThe metabolism of Desipramine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineDesipramine may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Desipramine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Desipramine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Desipramine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Desipramine.Approved
CrizotinibDesipramine may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Desipramine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desipramine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Desipramine.Approved, Investigational
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Desipramine.Approved
Cyproterone acetateThe serum concentration of Desipramine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desipramine.Approved
DabrafenibThe serum concentration of Desipramine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Desipramine is combined with Dantrolene.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Desipramine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desipramine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desipramine.Investigational
DarexabanThe serum concentration of Desipramine can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Desipramine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Desipramine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Desipramine.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Desipramine.Approved, Investigational
DeferasiroxThe serum concentration of Desipramine can be increased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Desipramine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Desipramine can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Desipramine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Desipramine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Desipramine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Desipramine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desipramine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Desipramine.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Desipramine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desipramine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Desipramine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Desipramine.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineDesipramine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Desipramine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Desipramine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Desipramine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Desipramine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desipramine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Desipramine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Desipramine.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Desipramine.Approved, Vet Approved
DicoumarolDesipramine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Desipramine.Experimental
DiethylpropionDesipramine may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Desipramine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Desipramine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Desipramine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Desipramine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Desipramine.Experimental
DihydroergotamineDesipramine may decrease the antihypertensive activities of Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desipramine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desipramine.Experimental, Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Desipramine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Desipramine.Approved
DiphenadioneDesipramine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Desipramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desipramine.Approved, Illicit
DipivefrinDesipramine may decrease the antihypertensive activities of Dipivefrin.Approved
DisopyramideDesipramine may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Desipramine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Desipramine is combined with Dobutamine.Approved
DofetilideDesipramine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronDesipramine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneDesipramine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Desipramine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Desipramine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Desipramine.Vet Approved
DosulepinThe metabolism of Desipramine can be decreased when combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Desipramine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Desipramine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Desipramine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Desipramine.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Desipramine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved, Illicit
DronedaroneDesipramine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Desipramine.Experimental, Illicit
DroxidopaDesipramine may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Desipramine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desipramine.Approved
EcabetThe serum concentration of Desipramine can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Desipramine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Desipramine.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Desipramine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Desipramine.Approved, Investigational
ElafinThe serum concentration of Desipramine can be increased when it is combined with Elafin.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Desipramine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Desipramine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Desipramine.Investigational
EnalaprilThe serum concentration of Desipramine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Desipramine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Desipramine can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Desipramine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Desipramine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Desipramine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Desipramine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Desipramine.Approved, Investigational
EphedraDesipramine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
Epigallocatechin GallateThe serum concentration of Desipramine can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Desipramine.Approved, Investigational
EpinephrineDesipramine may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desipramine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ergonovine.Approved
ErgotamineDesipramine may decrease the antihypertensive activities of Ergotamine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Desipramine.Approved, Investigational
ErythromycinDesipramine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Desipramine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Desipramine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Desipramine.Investigational
EsomeprazoleThe metabolism of Desipramine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Desipramine.Approved, Illicit
EstroneThe metabolism of Estrone can be decreased when combined with Desipramine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desipramine.Approved
EthanolDesipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desipramine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desipramine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desipramine.Approved
Ethyl biscoumacetateDesipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desipramine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Desipramine.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Desipramine.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Desipramine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Desipramine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Desipramine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Desipramine.Approved
EtomidateDesipramine may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Desipramine is combined with Etoperidone.Withdrawn
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Desipramine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Desipramine.Illicit, Vet Approved
EtravirineThe metabolism of Desipramine can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Desipramine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ezogabine.Approved
FaldaprevirThe serum concentration of Desipramine can be increased when it is combined with Faldaprevir.Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Desipramine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Desipramine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desipramine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desipramine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Desipramine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Desipramine.Approved, Investigational
FlecainideDesipramine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Desipramine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Desipramine.Experimental
FluconazoleThe metabolism of Desipramine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Desipramine.Approved, Illicit
FluindioneDesipramine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Desipramine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Desipramine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desipramine.Approved, Vet Approved
FlupentixolDesipramine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Desipramine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desipramine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Desipramine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Desipramine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Desipramine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desipramine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Desipramine.Approved, Investigational
FosamprenavirThe serum concentration of Desipramine can be increased when it is combined with Fosamprenavir.Approved
FosinoprilThe serum concentration of Desipramine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Desipramine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Desipramine.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Desipramine.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Desipramine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desipramine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Desipramine is combined with Gabapentin Enacarbil.Approved
GabexateThe serum concentration of Desipramine can be increased when it is combined with Gabexate.Investigational
Gadobenic acidDesipramine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Desipramine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Desipramine.Approved, Illicit, Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Desipramine.Approved, Investigational
GeldanamycinThe serum concentration of Desipramine can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilThe metabolism of Desipramine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinDesipramine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineDesipramine may increase the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Desipramine.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Desipramine.Approved, Illicit
GM6001The serum concentration of Desipramine can be increased when it is combined with GM6001.Experimental
GoserelinDesipramine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronDesipramine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzDesipramine may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineDesipramine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Desipramine.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Desipramine.Approved
HaloperidolDesipramine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Desipramine.Approved, Vet Approved
HarmalineHarmaline may increase the serotonergic activities of Desipramine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Desipramine.Approved, Illicit, Investigational
HexobarbitalThe metabolism of Desipramine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Desipramine.Experimental
HydrocodoneDesipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Desipramine.Approved, Illicit
HydroxyamphetamineDesipramine may increase the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Desipramine.Approved
IbutilideDesipramine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Desipramine.Approved
IdraparinuxThe serum concentration of Desipramine can be increased when it is combined with Idraparinux.Investigational
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Desipramine.Approved
IloperidoneDesipramine may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Desipramine.Approved
ImidaprilThe serum concentration of Desipramine can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Desipramine is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Desipramine can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Desipramine.Investigational
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Desipramine.Approved, Investigational
Iofetamine I-123Desipramine may increase the stimulatory activities of Iofetamine I-123.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Desipramine.Approved
IproclozideIproclozide may increase the serotonergic activities of Desipramine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Desipramine.Withdrawn
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Desipramine.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Desipramine is combined with Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Desipramine is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Desipramine.Approved, Vet Approved
IsoflurophateThe serum concentration of Desipramine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Desipramine can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Desipramine is combined with Isoprenaline.Approved
IxazomibThe serum concentration of Desipramine can be increased when it is combined with Ixazomib.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desipramine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Desipramine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Desipramine.Approved, Investigational
KetoconazoleThe metabolism of Desipramine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Desipramine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desipramine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Desipramine.Approved
LenvatinibDesipramine may increase the QTc-prolonging activities of Lenvatinib.Approved
LepirudinThe serum concentration of Desipramine can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Desipramine can be increased when it is combined with Letaxaban.Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Desipramine.Approved
LeuprolideDesipramine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Desipramine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Desipramine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Desipramine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Desipramine is combined with Levocetirizine.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Desipramine.Approved
LevofloxacinDesipramine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desipramine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Desipramine is combined with Levomilnacipran.Approved
LevonordefrinDesipramine may decrease the antihypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desipramine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Desipramine is combined with Levosalbutamol.Approved
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Desipramine.Approved
LidocaineThe metabolism of Desipramine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Desipramine can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Desipramine.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Desipramine.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Desipramine.Approved
LisdexamfetamineDesipramine may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Desipramine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Desipramine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Desipramine.Approved
LobeglitazoneThe metabolism of Desipramine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Desipramine.Illicit
LofexidineDesipramine may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Desipramine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Desipramine.Approved
LopinavirDesipramine may increase the QTc-prolonging activities of Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Desipramine.Experimental
LoratadineThe metabolism of Loratadine can be decreased when combined with Desipramine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Desipramine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Desipramine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Desipramine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Desipramine.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Desipramine.Approved
LuliconazoleThe serum concentration of Desipramine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Desipramine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineDesipramine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Desipramine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Desipramine.Illicit, Investigational, Withdrawn
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved, Vet Approved
MalathionThe metabolism of Malathion can be decreased when combined with Desipramine.Approved, Investigational
ManidipineThe metabolism of Desipramine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desipramine.Approved
MebanazineMebanazine may increase the serotonergic activities of Desipramine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Desipramine.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Desipramine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Desipramine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Desipramine.Vet Approved
MelagatranThe serum concentration of Desipramine can be increased when it is combined with Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Desipramine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Desipramine.Approved, Investigational
MephedroneDesipramine may increase the stimulatory activities of Mephedrone.Investigational
MephentermineDesipramine may increase the vasopressor activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Desipramine.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desipramine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desipramine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Desipramine.Experimental
MequitazineThe metabolism of Mequitazine can be decreased when combined with Desipramine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Desipramine.Approved, Investigational
MetaraminolDesipramine may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desipramine.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Desipramine.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Desipramine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Desipramine.Approved, Illicit
MethamphetamineDesipramine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Desipramine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Desipramine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desipramine.Approved, Vet Approved
MethohexitalThe metabolism of Desipramine can be increased when combined with Methohexital.Approved
MethotrimeprazineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineDesipramine may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Desipramine.Approved, Investigational, Vet Approved
MethoxyphenamineDesipramine may increase the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Desipramine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Desipramine.Experimental
Methylene blueDesipramine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Desipramine.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Desipramine.Approved, Investigational
MethylphenobarbitalThe metabolism of Desipramine can be increased when combined with Methylphenobarbital.Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Desipramine.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Desipramine.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Desipramine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Desipramine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Desipramine.Approved, Investigational
MetyrosineDesipramine may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Desipramine.Experimental
MexiletineThe metabolism of Desipramine can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Desipramine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Desipramine.Approved, Illicit
MidodrineDesipramine may increase the vasopressor activities of Midodrine.Approved
MidomafetamineDesipramine may increase the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Desipramine can be decreased when combined with Midostaurin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Desipramine.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Desipramine is combined with Milnacipran.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Desipramine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved, Investigational
MirabegronThe serum concentration of Desipramine can be increased when it is combined with Mirabegron.Approved
MirtazapineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDADesipramine may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Desipramine is combined with Moclobemide.Approved
ModafinilThe metabolism of Desipramine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Desipramine can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Desipramine.Approved
MoperoneThe risk or severity of adverse effects can be increased when Desipramine is combined with Moperone.Experimental
MorphineThe metabolism of Morphine can be decreased when combined with Desipramine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Mosapramine.Experimental
MoxifloxacinDesipramine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Desipramine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Desipramine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved, Investigational
NafamostatThe serum concentration of Desipramine can be increased when it is combined with Nafamostat.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desipramine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Desipramine.Approved
NaphazolineDesipramine may decrease the antihypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Desipramine.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Desipramine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Desipramine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Desipramine.Approved, Withdrawn
NelfinavirThe serum concentration of Desipramine can be increased when it is combined with Nelfinavir.Approved
NetupitantThe metabolism of Netupitant can be decreased when combined with Desipramine.Approved
NevirapineThe metabolism of Desipramine can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Desipramine.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Desipramine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Desipramine.Approved, Investigational
NicorandilDesipramine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Desipramine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Desipramine.Approved
NilotinibDesipramine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Desipramine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Desipramine.Approved
NitroaspirinThe serum concentration of Desipramine can be increased when it is combined with Nitroaspirin.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Desipramine.Approved, Investigational, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Desipramine.Approved, Vet Approved
NorepinephrineDesipramine may decrease the antihypertensive activities of Norepinephrine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Desipramine.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Desipramine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desipramine.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Desipramine.Withdrawn
OfloxacinDesipramine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Desipramine.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desipramine.Approved
OmapatrilatThe serum concentration of Desipramine can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Desipramine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronDesipramine may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Desipramine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Desipramine is combined with Orciprenaline.Approved
OrphenadrineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Desipramine.Investigational
OsimertinibThe serum concentration of Desipramine can be decreased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Desipramine.Approved
OtamixabanThe serum concentration of Desipramine can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desipramine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Desipramine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Desipramine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Desipramine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Desipramine.Approved, Illicit, Investigational
OxymetazolineDesipramine may decrease the antihypertensive activities of Oxymetazoline.Approved
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Desipramine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Desipramine is combined with Oxypertine.Experimental
PaliperidoneDesipramine may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Desipramine.Approved, Investigational
PanobinostatThe serum concentration of Desipramine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Desipramine can be decreased when combined with Pantoprazole.Approved
ParaldehydeDesipramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylinePargyline may increase the serotonergic activities of Desipramine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desipramine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Desipramine.Approved
Peginterferon alfa-2bThe serum concentration of Desipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Desipramine.Experimental
PentamidineDesipramine may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desipramine.Approved, Vet Approved
PentobarbitalThe metabolism of Desipramine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Desipramine.Investigational
PerflutrenDesipramine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideDesipramine may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Desipramine.Approved, Investigational
PerindoprilThe serum concentration of Desipramine can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Desipramine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Desipramine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Desipramine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desipramine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Desipramine.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Desipramine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Desipramine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Desipramine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Desipramine.Experimental
PhenindioneDesipramine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Desipramine.Withdrawn
PhenobarbitalThe metabolism of Desipramine can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Desipramine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Desipramine.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Desipramine.Withdrawn
PhenprocoumonDesipramine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineDesipramine may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylephrineDesipramine may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Desipramine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Desipramine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Desipramine can be increased when it is combined with Phosphoramidon.Experimental
PimozideDesipramine may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Desipramine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Desipramine.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Desipramine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Desipramine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Desipramine.Investigational
PirlindolePirlindole may increase the serotonergic activities of Desipramine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Desipramine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Desipramine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Desipramine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Desipramine is combined with Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Desipramine.Approved
PramipexoleDesipramine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Desipramine.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Desipramine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Desipramine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Desipramine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Desipramine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Desipramine.Approved
PrimaquineDesipramine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Desipramine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Desipramine can be increased when it is combined with Prinomastat.Investigational
ProcainamideDesipramine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Desipramine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Procaterol.Approved, Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Desipramine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Desipramine.Approved, Vet Approved
PromazineDesipramine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Desipramine.Approved
PropafenoneThe serum concentration of Desipramine can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Desipramine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Desipramine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Propericiazine.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Desipramine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Desipramine.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Desipramine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Desipramine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desipramine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Desipramine.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Desipramine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Desipramine.Investigational
PseudoephedrineDesipramine may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Desipramine.Approved, Illicit
QuetiapineDesipramine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe serum concentration of Desipramine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineDesipramine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineDesipramine may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Desipramine.Experimental
RacecadotrilThe serum concentration of Desipramine can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Desipramine.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Desipramine.Approved, Investigational
RamiprilThe serum concentration of Desipramine can be increased when it is combined with Ramipril.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Desipramine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Desipramine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Desipramine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desipramine.Approved
RemikirenThe serum concentration of Desipramine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Desipramine.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Desipramine.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Desipramine.Approved, Investigational
RifampicinThe metabolism of Desipramine can be increased when combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Desipramine.Approved, Investigational
RisperidoneDesipramine may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Desipramine.Investigational
RitobegronDesipramine may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Desipramine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Desipramine can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Desipramine.Approved
RolapitantThe metabolism of Desipramine can be decreased when combined with Rolapitant.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Desipramine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Desipramine.Vet Approved
RopiniroleDesipramine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Desipramine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Desipramine.Approved
RotigotineDesipramine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Desipramine.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Desipramine.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Desipramine.Approved
S-3304The serum concentration of Desipramine can be increased when it is combined with S-3304.Investigational
SafrazineSafrazine may increase the serotonergic activities of Desipramine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Desipramine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Salmeterol.Approved
SaquinavirThe serum concentration of Desipramine can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Desipramine can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desipramine.Approved
SecobarbitalThe metabolism of Desipramine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Desipramine.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Desipramine.Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Desipramine.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Desipramine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Desipramine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Desipramine.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Desipramine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Desipramine.Approved
SimeprevirThe serum concentration of Desipramine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Desipramine.Approved
SitagliptinThe serum concentration of Desipramine can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Desipramine can be increased when it is combined with Sivelestat.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
Sodium phosphateThe risk or severity of adverse effects can be increased when Desipramine is combined with Sodium phosphate.Approved
SorafenibThe metabolism of Sorafenib can be decreased when combined with Desipramine.Approved, Investigational
SotalolDesipramine may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Desipramine.Experimental
SpiraprilThe serum concentration of Desipramine can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Desipramine can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe metabolism of Desipramine can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desipramine.Approved, Investigational
SulfisoxazoleDesipramine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Desipramine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Desipramine.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Desipramine.Approved, Investigational
SuvorexantDesipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Desipramine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Desipramine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Desipramine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Desipramine is combined with Tasimelteon.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Desipramine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Desipramine.Investigational, Withdrawn
TelaprevirThe serum concentration of Desipramine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinDesipramine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinDesipramine may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Desipramine.Approved
TemocaprilThe serum concentration of Desipramine can be increased when it is combined with Temocapril.Experimental, Investigational
Tenofovir disoproxilThe metabolism of Desipramine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Desipramine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Desipramine is combined with Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Desipramine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Desipramine.Experimental
TeriflunomideThe serum concentration of Desipramine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Desipramine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Desipramine.Approved, Investigational
TetrabenazineDesipramine may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Desipramine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Desipramine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Desipramine.Investigational
ThalidomideDesipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Desipramine can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Desipramine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Desipramine can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Desipramine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Desipramine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Desipramine.Approved, Withdrawn
ThiorphanThe serum concentration of Desipramine can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Desipramine.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Desipramine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Desipramine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Desipramine.Approved, Investigational
TiclopidineThe metabolism of Desipramine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Desipramine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Desipramine.Experimental
TimololThe metabolism of Timolol can be decreased when combined with Desipramine.Approved
TioclomarolDesipramine may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Desipramine.Approved
TipranavirThe metabolism of Desipramine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineDesipramine may decrease the antihypertensive activities of Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desipramine.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Desipramine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Desipramine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Desipramine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Desipramine.Approved, Investigational
ToremifeneDesipramine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Desipramine.Approved, Investigational
TramadolDesipramine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Desipramine can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Desipramine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Desipramine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Desipramine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Desipramine.Approved, Investigational, Nutraceutical
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Desipramine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Desipramine.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Desipramine.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desipramine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Desipramine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Desipramine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Desipramine.Approved
TropisetronTropisetron may increase the serotonergic activities of Desipramine.Approved, Investigational
UbenimexThe serum concentration of Desipramine can be increased when it is combined with Ubenimex.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Desipramine.Approved, Experimental
UlinastatinThe serum concentration of Desipramine can be increased when it is combined with Ulinastatin.Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Desipramine.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Desipramine.Approved, Investigational
Valproic AcidThe serum concentration of Desipramine can be increased when it is combined with Valproic Acid.Approved, Investigational
VandetanibDesipramine may increase the QTc-prolonging activities of Vandetanib.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Desipramine.Approved
VemurafenibThe serum concentration of Desipramine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Desipramine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Desipramine.Experimental
VerapamilThe metabolism of Verapamil can be decreased when combined with Desipramine.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Desipramine.Approved, Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Desipramine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Desipramine.Approved
VildagliptinThe serum concentration of Desipramine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Desipramine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Desipramine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Desipramine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Desipramine.Experimental
VoriconazoleThe metabolism of Desipramine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Desipramine.Approved
WarfarinDesipramine may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Desipramine.Experimental
XimelagatranThe serum concentration of Desipramine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Desipramine.Vet Approved
XylometazolineDesipramine may decrease the antihypertensive activities of Xylometazoline.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Desipramine.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Desipramine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Desipramine.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desipramine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Desipramine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Desipramine is combined with Zimelidine.Withdrawn
ZiprasidoneDesipramine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZofenoprilThe serum concentration of Desipramine can be increased when it is combined with Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Desipramine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Desipramine.Approved, Investigational
ZolpidemDesipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Desipramine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Desipramine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Desipramine.Approved, Investigational
ZucapsaicinThe metabolism of Desipramine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolDesipramine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation, limit caffeine intake.

References

Synthesis Reference

Biel, J.H.and Judd, C.I.; US. Patent 3,454,554; July 8,1969; assigned to Colgate Palmolive Co.

General References
Not Available
External Links
Human Metabolome Database
HMDB15282
KEGG Drug
D07791
KEGG Compound
C06943
PubChem Compound
2995
PubChem Substance
46504624
ChemSpider
2888
BindingDB
35229
ChEBI
47781
ChEMBL
CHEMBL72
Therapeutic Targets Database
DAP001151
PharmGKB
PA449233
IUPHAR
2399
Guide to Pharmacology
GtP Drug Page
HET
DSM
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Desipramine
ATC Codes
N06AA01 — Desipramine
AHFS Codes
  • 28:16.04.28 — Tricyclics and Other Norepinephrine-reuptake Inhibitors
PDB Entries
2qb4 / 2qju
FDA label
Download (152 KB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Mirabegron1
1CompletedTreatmentCancers1
1CompletedTreatmentDepression2
1CompletedTreatmentErectile Dysfunction (ED)1
1CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentAlcoholism / Dual Diagnosis / Schizophrenic Disorders1
2CompletedTreatmentBack Pain1
2CompletedTreatmentBack Pain / Sciatica1
2CompletedTreatmentCocaine-Related Disorders1
2CompletedTreatmentCocaine-Related Disorders / Substance-Related Disorders2
2CompletedTreatmentRett's Syndrome1
2CompletedTreatmentSleep Apnea, Obstructive2
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3CompletedTreatmentAbdominal Pain (AP) / Functional Colonic Diseases / Irritable Bowel Syndrome (IBS) / Occasional Constipation1
3CompletedTreatmentAlcoholism / Depression / PTSD1
3CompletedTreatmentDepression1
3CompletedTreatmentDepression / Depressive Disorders / Major Depressive Disorder (MDD)1
3CompletedTreatmentGERD1
3CompletedTreatmentHerpes Zoster / Pain1
4CompletedTreatmentDepression1
4CompletedTreatmentMajor Depressive Disorder (MDD)1
4CompletedTreatmentSubstance-Related Disorders1
Not AvailableActive Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
Not AvailableCompletedTreatmentAnxiety Disorders / Depression / Drug-resistant Depression / Personality Disorders1
Not AvailableCompletedTreatmentDepression2
Not AvailableUnknown StatusTreatmentFunctional Dyspepsia1
Not AvailableUnknown StatusTreatmentIrritable Bowel Syndrome (IBS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral25 mg
TabletOral50 mg
TabletOral75 mg
TabletOral10 mg/1
TabletOral100 mg/1
TabletOral150 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
TabletOral75 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coatedOral75 mg/1
Tablet, sugar coatedOral10 mg/1
Tablet, sugar coatedOral100 mg/1
Tablet, sugar coatedOral150 mg/1
Tablet, sugar coatedOral25 mg/1
Tablet, sugar coatedOral50 mg/1
Tablet, sugar coatedOral75 mg/1
TabletOral100 mg
Prices
Unit descriptionCostUnit
Desipramine hcl powder14.4USD g
Norpramin 150 mg tablet6.08USD tablet
Desipramine HCl 150 mg tablet4.67USD tablet
Norpramin 100 mg tablet4.2USD tablet
Norpramin 75 mg tablet3.19USD tablet
Desipramine HCl 100 mg tablet2.81USD tablet
Desipramine HCl 75 mg tablet2.63USD tablet
Norpramin 50 mg tablet2.51USD tablet
Desipramine 150 mg tablet2.18USD tablet
Desipramine HCl 50 mg tablet1.64USD tablet
Desipramine 100 mg tablet1.5USD tablet
Norpramin 25 mg tablet1.33USD tablet
Desipramine 75 mg tablet1.15USD tablet
Norpramin 10 mg tablet1.11USD tablet
Apo-Desipramine 75 mg Tablet0.93USD tablet
Desipramine 50 mg tablet0.92USD tablet
Desipramine HCl 10 mg tablet0.87USD tablet
Desipramine HCl 25 mg tablet0.83USD tablet
Apo-Desipramine 50 mg Tablet0.7USD tablet
Desipramine 25 mg tablet0.49USD tablet
Desipramine 10 mg tablet0.4USD tablet
Apo-Desipramine 10 mg Tablet0.4USD tablet
Apo-Desipramine 25 mg Tablet0.4USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)214-218 °CNot Available
water solubility58.6 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.90HANSCH,C ET AL. (1995)
logS-3.66ADME Research, USCD
Caco2 permeability-4.67ADME Research, USCD
pKa10.4SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0396 mg/mLALOGPS
logP4.02ALOGPS
logP3.9ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)10.02ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area15.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity85.31 m3·mol-1ChemAxon
Polarizability31.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9958
Blood Brain Barrier+0.9854
Caco-2 permeable+0.8868
P-glycoprotein substrateSubstrate0.7945
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.6353
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.7684
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.5117
CYP450 1A2 substrateInhibitor0.9029
CYP450 2C9 inhibitorNon-inhibitor0.9125
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9241
CYP450 3A4 inhibitorInhibitor0.744
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8478
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9476
BiodegradationNot ready biodegradable0.9686
Rat acute toxicity2.8197 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8569
hERG inhibition (predictor II)Inhibitor0.8604
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (11 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0544-7980000000-e155fe1ae5cd0aa22da3
Mass Spectrum (Electron Ionization)MSsplash10-0006-4970000000-810535cb33c37107abc5
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzazepines
Sub Class
Dibenzazepines
Direct Parent
Dibenzazepines
Alternative Parents
Alkyldiarylamines / Azepines / Benzenoids / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Dibenzazepine / Alkyldiarylamine / Tertiary aliphatic/aromatic amine / Azepine / Benzenoid / Tertiary amine / Azacycle / Secondary amine / Secondary aliphatic amine / Organic nitrogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
secondary amino compound, dibenzoazepine (CHEBI:47781)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Zavosh A, Schaefer J, Ferrel A, Figlewicz DP: Desipramine treatment decreases 3H-nisoxetine binding and norepinephrine transporter mRNA in SK-N-SHSY5Y cells. Brain Res Bull. 1999 Jul 1;49(4):291-5. [PubMed:10424850]
  2. Weinshenker D, White SS, Javors MA, Palmiter RD, Szot P: Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo. Brain Res. 2002 Aug 16;946(2):239-46. [PubMed:12137927]
  3. Bryan-Lluka LJ, Bonisch H, Lewis RJ: chi-Conopeptide MrIA partially overlaps desipramine and cocaine binding sites on the human norepinephrine transporter. J Biol Chem. 2003 Oct 10;278(41):40324-9. Epub 2003 Jul 1. [PubMed:12837768]
  4. Zhu MY, Kyle PB, Hume AS, Ordway GA: The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function. Neurochem Res. 2004 Feb;29(2):419-27. [PubMed:15002740]
  5. Ordway GA, Jia W, Li J, Zhu MY, Mandela P, Pan J: Norepinephrine transporter function and desipramine: residual drug effects versus short-term regulation. J Neurosci Methods. 2005 Apr 30;143(2):217-25. Epub 2004 Dec 30. [PubMed:15814154]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Holmes A, Yang RJ, Murphy DL, Crawley JN: Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology. 2002 Dec;27(6):914-23. [PubMed:12464448]
  2. Gould GG, Altamirano AV, Javors MA, Frazer A: A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol Psychiatry. 2006 Mar 1;59(5):408-14. Epub 2005 Sep 2. [PubMed:16140280]
  3. Zhou L, Huang KX, Kecojevic A, Welsh AM, Koliatsos VE: Evidence that serotonin reuptake modulators increase the density of serotonin innervation in the forebrain. J Neurochem. 2006 Jan;96(2):396-406. Epub 2005 Nov 21. [PubMed:16300628]
  4. Hoffman AF, Gerhardt GA: In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions. J Neurochem. 1998 Jan;70(1):179-89. [PubMed:9422361]
  5. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Matsumoto K, Ojima K, Ohta H, Watanabe H: Beta 2- but not beta 1-adrenoceptors are involved in desipramine enhancement of aggressive behavior in long-term isolated mice. Pharmacol Biochem Behav. 1994 Sep;49(1):13-8. [PubMed:7816863]
  2. Sapena R, Morin D, Zini R, Morin C, Tillement JP: Desipramine treatment differently down-regulates beta-adrenoceptors of freshly isolated neurons and astrocytes. Eur J Pharmacol. 1996 Apr 4;300(1-2):159-62. [PubMed:8741184]
  3. Abadie C, Foucart S, Page P, Nadeau R: Modulation of noradrenaline release from isolated human atrial appendages. J Auton Nerv Syst. 1996 Dec 14;61(3):269-76. [PubMed:8988485]
  4. Prenner L, Sieben A, Zeller K, Weiser D, Haberlein H: Reduction of high-affinity beta2-adrenergic receptor binding by hyperforin and hyperoside on rat C6 glioblastoma cells measured by fluorescence correlation spectroscopy. Biochemistry. 2007 May 1;46(17):5106-13. Epub 2007 Apr 7. [PubMed:17417877]
  5. Osadchii OE, Woodiwiss AJ, Deftereos D, Norton GR: Temporal changes in myocardial adrenergic regulation with the progression to pump dysfunction after chronic beta-adrenoreceptor activation in rats. Pflugers Arch. 2007 Nov;455(2):251-60. Epub 2007 Jun 9. [PubMed:17558518]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Sapena R, Morin D, Zini R, Morin C, Tillement JP: Desipramine treatment differently down-regulates beta-adrenoceptors of freshly isolated neurons and astrocytes. Eur J Pharmacol. 1996 Apr 4;300(1-2):159-62. [PubMed:8741184]
  2. Burgi S, Baltensperger K, Honegger UE: Antidepressant-induced switch of beta 1-adrenoceptor trafficking as a mechanism for drug action. J Biol Chem. 2003 Jan 10;278(2):1044-52. Epub 2002 Oct 21. [PubMed:12393876]
  3. Matsumoto K, Ojima K, Ohta H, Watanabe H: Beta 2- but not beta 1-adrenoceptors are involved in desipramine enhancement of aggressive behavior in long-term isolated mice. Pharmacol Biochem Behav. 1994 Sep;49(1):13-8. [PubMed:7816863]
  4. Samnick S, Scheuer C, Munks S, El-Gibaly AM, Menger MD, Kirsch CM: Technetium-99m labeled 1-(4-fluorobenzyl)-4-(2-mercapto-2-methyl-4-azapentyl)-4-(2-mercapto-2-methylprop ylamino)-piperidine and iodine-123 metaiodobenzylguanidine for studying cardiac adrenergic function: a comparison of the uptake characteristics in vascular smooth muscle cells and neonatal cardiac myocytes, and an investigation in rats. Nucl Med Biol. 2004 May;31(4):511-22. [PubMed:15093822]
  5. Mudunkotuwa NT, Horton RW: Desipramine administration in the olfactory bulbectomized rat: changes in brain beta-adrenoceptor and 5-HT2A binding sites and their relationship to behaviour. Br J Pharmacol. 1996 Apr;117(7):1481-6. [PubMed:8730743]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sphingomyelin phosphodiesterase activity
Specific Function
Converts sphingomyelin to ceramide. Also has phospholipase C activities toward 1,2-diacylglycerolphosphocholine and 1,2-diacylglycerolphosphoglycerol. Isoform 2 and isoform 3 have lost catalytic ac...
Gene Name
SMPD1
Uniprot ID
P17405
Uniprot Name
Sphingomyelin phosphodiesterase
Molecular Weight
69751.3 Da
References
  1. Testai FD, Landek MA, Dawson G: Regulation of sphingomyelinases in cells of the oligodendrocyte lineage. J Neurosci Res. 2004 Jan 1;75(1):66-74. [PubMed:14689449]
  2. Kolzer M, Werth N, Sandhoff K: Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett. 2004 Feb 13;559(1-3):96-8. [PubMed:14960314]
  3. Erdreich-Epstein A, Tran LB, Cox OT, Huang EY, Laug WE, Shimada H, Millard M: Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathways. Blood. 2005 Jun 1;105(11):4353-61. Epub 2005 Feb 10. [PubMed:15705795]
  4. Zeidan YH, Pettus BJ, Elojeimy S, Taha T, Obeid LM, Kawamori T, Norris JS, Hannun YA: Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-{alpha}-induced PGE2 production. J Biol Chem. 2006 Aug 25;281(34):24695-703. Epub 2006 Jun 27. [PubMed:16803890]
  5. Hurwitz R, Ferlinz K, Sandhoff K: The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler. 1994 Jul;375(7):447-50. [PubMed:7945993]
  6. Kornhuber J, Tripal P, Reichel M, Muhle C, Rhein C, Muehlbacher M, Groemer TW, Gulbins E: Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2010;26(1):9-20. doi: 10.1159/000315101. Epub 2010 May 18. [PubMed:20502000]
Details
7. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Sawynok J, Esser MJ, Reid AR: Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. Pain. 1999 Aug;82(2):149-58. [PubMed:10467920]
  2. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein group
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  3. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  3. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J: Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl). 1996 Aug;126(3):234-40. [PubMed:8876023]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...

Components:
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Lewis DF, Modi S, Dickins M: Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82. [PubMed:11996013]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880]
  2. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001 Sep;281(3):F454-68. [PubMed:11502595]
  3. Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H: Drug excretion mediated by a new prototype of polyspecific transporter. Nature. 1994 Dec 8;372(6506):549-52. [PubMed:7990927]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81. [PubMed:9260930]
  2. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001 Sep;281(3):F454-68. [PubMed:11502595]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. [PubMed:10966924]
  2. Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V: Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem. 1998 Jun 26;273(26):15971-9. [PubMed:9632645]
  3. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. [PubMed:10454528]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name
SLC22A4
Uniprot ID
Q9H015
Uniprot Name
Solute carrier family 22 member 4
Molecular Weight
62154.48 Da
References
  1. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. [PubMed:10825452]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34